Translational aspects of the novel object recognition task in rats abstinent following sub-chronic treatment with phencyclidine (PCP): Effects of modafinil and relevance to cognitive deficits in schizophrenia

Frontiers in Psychiatry

Volumn 1, Issue NOV, 2010, Pages

  Redrobe, John P ^a   Bull, Sascha ^a   Plath, Niels ^a  

^a Department of In Vivo Neuropharmacology ^*  (Denmark)

Author keywords

Cognition; Modafinil; Novel object recognition; Phencyclidine; Rat; Schizophrenia

Indexed keywords

EID: 84858621009     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2010.00146     Document Type: Article

References (65)

1. Abdul-Monim, Z., Neill, J. C., and Reynolds, G. P. (2007). Sub-chronic psychomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. J. Pshychopharmacol. 21, 198-205.
2. Aleman, A., Hijman, R., de Haan, E. H., and Kahn, R. S. (1999). Memory impairment in schizophrenia: a meta-analysis. Am. J. Psychiatry 156, 1358-1366.
3. Birrell, J. M., and Brown, V. J. (2000). Medial frontal cortex mediates perceptual attentional set shifting in the rat. J. Neurosci. 20, 4320-4324.
4. Buchanan, R. W., Summerfelt, A., Tek, C., and Gold, J. (2003). An openlabeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr. Res. 59, 29-33.
5. Clare, L., McKenna, P. J., Mortimer, A. M., and Baddeley, A. D. (1993). Memory in schizophrenia: What is impaired and what is preserved? Neuropsychologia 31, 1225-1241.
6. Clark, R. E., Zola, S. M., and Squire, L. R. (2000). Impaired recognition memory in rats after damage to the hippocampus. J. Neurosci. 20, 8853-8860.
7. Chung, Y. C., Lee, C. R., Park, T. W., Yang, K. H., and Kim, K.W. (2009). Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial. World J. Biol. Psychiatry 10, 156-162.
8. Damgaard, T., Larsen, D. B., Hansen, S. L., Grayson, B., Neill, J. C., and Plath N. (2010). Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats. Behav. Brain Res. 207, 144-150.
9. Davidson, M., Galderisi, S., Weiser, M., Werbeloff, N., Fleischhacker, W. W., Keefe, R. S., Boter, H., Keet, I. P., Prelipceanu, D., Rybakowski, J. K., Libiger, J., Hummer, M., Dollfus, S., López-Ibor, J. J., Hranov, L. G., Gaebel, W., Peuskens, J., Lindefors, N., Riecher-Rössler, A., and Kahn, R. S. (2009). Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-lable clinical trial (EUFEST). Am. J. Psychiatry 166, 675-682.
10. Egerton, A., Reid, L., McKerchar, C. E., Morris, B. J., and Pratt, J. A. (2005). Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia. Psychopharmacology 179, 77-84.
11. Ennaceur, A., and Delacour, J. (1988). A new one-trial test for neurobiological studies of memory in rats. 1: behavioural data. Behav. Brain Res. 31, 47-59.
12. Enomoto, T., Noda, Y., and Nabeshima, T. (2007). Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis. Methods Find. Exp. Clin. Pharmacol. 29, 291-301.
13. Fett, A. K., Viechtbauer, W., Dominguez, M. D., Penn, D. L., van Os, J., and Krabbendam, L. (2010). The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci. Biobehav. Rev. doi: 10.1016/j.neubiorev.2010.07.001.
14. Friedman, J. I., Adler, D. N., Howanitz, E., Harvey, P. D., Brenner, G., Temporini, H., White, L., Parrella, M., and Davis, K. L. (2002). A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol. Psychiatry 51, 349-357.
15. Goetghebeur, P., and Dias, R. (2009). Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat: a back translational study. Pyschopharmacology 202, 287-293.
16. Grayson, B., Idris, N. F., and Neill, J. C. (2007). Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav. Brain Res. 184, 31-38.
17. Green, M. F., Nuechterlein, K. H., Gold, J. M., Barch, D. M., Cohen, J., Essock, S., Fenton, W. S., Frese, F., Goldberg, T. E., Heaton, R. K., Keefe, R. S., Kern, R. S., Kraemer, H., Stover, E., Weinberger, D. R., Zalcman, S., and Marder, S. R. (2004). Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol. Psychiatry 56, 301-307.
18. Harvey, P. D., and Keefe, R. S. E. (2001). Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry 158, 176-184.
19. Heckers, S., Curran, T., Goff, D., Rauch, S. L., Fischman, A. J., Alpert, N. M., and Schacter, D. L. (2000). Abnormalities in the thalamus and prefrontal cortex during episodic object recognition in schizophrenia. Biol. Psychiatry 48, 651-657.
20. Hetem, L. A., Danion, J. M., Diemunsch, P., and Brandt, C. (2000). Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers. Psychopharmacology 152, 283-288.
21. Honey, G. D., Honey, R. A., Sharar, S. R., Turner, D. C., Pomarol-Clotet, E., Kumaran, D., Simons, J. S., Hu, X., Rugg, M. D., Bullmore, E. T., and Fletcher, P. C. (2005). Impairment of specific episodic memory processes by sub-psychotic doses of ketamine: the effects of levels of processing at encoding and of the subsequent retrieval task. Psychopharmacology 181, 445-457.
22. Hunter, M. D., Ganesan, V., Wilkinson, I. D., and Spence, S. A. (2006). Impact of modafinilon prefrontal executive function in schizophrenia. Am. J. Psychiatry 163, 2184-2186.
23. Idris, N., Neill, J., Grayson, B., Bang-Andersen, B., Witten, L. M., Brennum, L. T., and Arnt, J. (2010). Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT(2A) receptor mechanisms. Psychopharmacology 208, 23-36.
24. Jentsch, J. D., and Roth, R. H. (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20, 201-225.
25. Keefe, R. S., Bilder, R. M., Davis, S. M., Harvey, P. D., Palmer, B. W., Gold, J. M., Meltzer, H. Y., Green, M. F., Capuano, G., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Davis, C. E., Hsiao, J. K., Lieberman, J. A., CATIE Investigators, and Neurocognitive Working Group. (2007a). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch. Gen. Psychiatry 64, 633-647.
26. Keefe, R. S., Malhotra, A. K., Meltzer, H. Y., Kane, J. M., Buchanan, R. W., Murthy, A., Sovel, M., Li, C., and Goldman, R. (2007b). Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo//practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 33, 1217-1228.
27. Kumar, R. (2008). Approved and investigational uses of modafinil: an evidence-based review. Drugs 68, 1803-1839.
28. Kunitachi, S., Fujita, Y., Ishima, T., Kohno, M., Horio, M., Tanibuchi, Y., Shirayama, Y., Iyo, M., and Hashimoto, K. (2009). Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: role of sigma-1 receptors. Brain Res. 1279, 189-196.
29. Lahti, A., Koffel, B., LaPorte, D., and Tamminga, C. A. (1995). Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13, 9-19.
30. Le Cozannet, R., Fone, K. C., and Moran, P. M. (2010). Phencyclidine withdrawal disrupts episodic-like memory in rats: reversal by donepezil but not clozapine. Int. J. Neuropsychopharmacol. 13, 1011-1020.
31. Lee, B. J., Lee, J. G., and Kim, Y. H. (2007). A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. J. Psychopharmacol. 21, 421-427.
32. Madras, B. K., Xie, Z., Lin, Z., Jassen, A., Panas, H., Lynch, L., Johnson, R., Livni, E., Spencer, T. J., Bonab, A. A., Miller, G. M., and Fischman, A. J. (2006). Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates transporters and trace amine activity in vitro. J. Pharmacol. Exp. Ther. 319, 561-569.
33. Manns, J. R., Stark, C. E. L., and Squire, L. R. (2000). The visual paired-comparison task as a measure of declarative memory. Proc. Natl. Acad. Sci. U.S.A. 97, 12375-12379.
34. McLean, S. L., Grayson, B., Idris, N. F., Lesage, A. S., Pemberton, D. J., Mackie, C., and Neill, J. C. (2010). Activation of alpha7 nicotinic recep-tors improves phencyclidine-induced deficits in cognitive tasks in rats: implications for therapy of cognitive dysfunction in schizophrenia. Eur. Neuropsychopharmacol. doi: 10.1016/j. neuroeuro.2010.06.003.
35. Minzenberg, M. J., and Carter, C. S. (2008). Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 33, 1477-1502.
36. Morein-Zamir, S., Turner, D. C., and Sahakian, B. J. (2007). A review of the effects of modafinil on cognition in schizophrenia. Schizophr. Bull. 33, 1298-1306.
37. Müller, U., Steffenhagen, N., Regenthal, R., and Bublak, P. (2004). Effects of modafinil on working memory processes in humans. Psychopharmacology 177, 161-169.
38. Neill, J. C., Barnes, S., Cook, S., Grayson, B., Idris, N. F., McLean, S. L., Snigdha, S., Rajagopal, L., and Harte, M. K. (2010). Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol. Ther. doi: 10.1016/j.pharmthera.2010.07.004.
39. O'Tuathaigh, C. M., and Waddington, J. L. (2010). Mutant mouse models: phenotypic relationships to domains of psychopathology and pathobiology in schizophrenia. Schizophr. Bull. 36, 243-245.
40. Patel, N. H., Vyas, N. S., Puri, B. K., Nijran, K. S., and Al-Nahhas, A. (2010). Positron emission tomography in scizophrenia: a new perspective. J. Nucl. Med. 51, 511-520.
41. Pierre, J. M., Peloian, J. H., Wirshing, D. A., Wirshing, W. C., and Marder, S. R. (2007). A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. J. Clin. Psychiatry 68, 705-710.
42. Pigeau, R., Naitoh, P., Buguet, A., McCann, C., Baranski, J., Taylor, M., Thompson, M., and Mack, II. (1995). Modafinil, d-amphetamine and placebo during 64 h of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperature. J. Sleep Res. 4, 212-228.
43. Pratt, J. A., Winchester, C., Egerton, A., Cochran, S. M., and Morris, B. J. (2008). Modelling prefrontal cortex deficits in schizophrenia: implications for treatment. Br. J. Pharmacol. 153(Suppl. 1), S465-S470.
44. Randall, D. C., Shneerson, J. M., and File, S. E. (2005). Cognitive effects of modafinil in student volunteers may depend on IQ. Pharmacol. Biochem. Behav. 82, 133-139.
45. Ribeiz, S. R., Bassitt, D. P., Arrais, J. A., Avila, R., Steffens, D. C., and Bottino, C. M. (2010). Cholinesterase inhibi-Redrobe et al. Translational validation of object recognition tors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and metaanalysis of the literature. CNS Drugs 24, 303-317.
46. Rodefer, J. S., Murphy, E. R., and Baxter, M. G. (2005). PDE10A inhibition reverses PCP-induced deficits in attentional set-shifting in rats. Eur. J. Neurosci. 21, 1070-1076.
47. Rodefer, J. S., Nguyen, T. N., Karlsson, J. J., and Arnt, J. (2008). Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT6 receptor antagonist: comparison among antipsychotics. Neuropsychopharmacology 33, 2657-2666.
48. Rosenthal, M. H., and Bryant, S. L. (2004). Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia. Clin. Neuropharmacol. 27, 38-43.
49. Rutten, K., Reneerkens, O. A., Hamers, H., Sik, A., McGregor, I. S., Prickaerts, J., and Blokland, A. (2008). Automated scoring of novel object recognition in rats. J. Neurosci. Methods 171, 72-77.
50. Saavedra-Velez, C., Yusim, A., Anbarasan, D., and Lindenmayer, J. P. (2009). Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. J. Clin. Psychiatry 70, 104-112.
51. Sambeth, A., Riedel, W. J., Smits, L. T., and Blokland, A. (2007). Cholinergic drugs affect novel object recognition in rats: relation with hippocampal EEG? Eur. J. Pharmacol. 572, 151-159.
52. Seillier, A., and Giuffrida, A. (2009). Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801. Behav. Brain Res. 204, 410-415.
53. Sevy, S., Rosenthal, M. H., Alvir, J., Meyer, S., Visweswaraiah, H., Gunduz-Bruce, H., and Schooler, N. R. (2005). Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenic patients treated with psychotropic medications. J. Clin. Psychiatry 66, 839-843.
54. Sharma, T., and Antonova, L. (2003). Cognitive function in schizophrenia: deficits, functional consequences, and future treatment. Psychiatr. Clin. North Am. 26, 25-40.
55. Snigdha, S., Horiguchi, M., Huang, M., Li, Z., Shahid, M., Neill, J. C., and Meltzer, H. Y. (2010). Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimivanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. J. Pharmacol. Exp. Ther. 332, 622-631.
56. Spence, S. A., Green, R. D., Wilkinson, I. D., and Hunter, M. D. (2005). Modafinil modulates anterior cingulated function in chronic schizophrenia. Br. J. Psychiatry 187, 55-61.
57. Stip, E., Sepehry, A. A., and Chouinard, S. (2007). Add-on therapy with acetylcholinesterase inhibitors for memory dysfunction in schizophrenia: a systematic quantitative review, part 2. Clin. Neuropharmacol. 30, 218-229.
58. Tek, C., Gold, J., Blaxton, T., Wilk, C., McMahon, R. P., and Buchanan, R. W. (2002). Visual perceptual and working memory impairments in schizophrenia. Arch. Gen. Psychiatry 59, 146-153.
59. Tugal, O., Yazici, K. M., Anil Yagcioglu, A. E., and Gögüg, A. (2004). A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int. J. Neuropsychopharmacol. 7, 117-123.
60. Turner, D. C., Robbins, T. W., Clark, L., Aron, A. R., Dowson, J., and Sahakian, B. J. (2003). Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology 165, 260-269.
61. Turner, D. C., Clark, L., Pomarol-Clotet, E., McKenna, P., Robbins, T. W., and Sahakian, B. J. (2004). Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 29, 1363-1373.
62. Waters, K. A., Burnham, K. E., O'Connor, D., Dawson, G. R., and Dias, R. (2005). Assessment of modafinil on attentional processes in a five-choice serial reaction time test in the rat. J. Psychopharmacol. 19, 149-158.
63. Wesensten, N. J., Killgore, W. D., and Balkin, T. J. (2005). Performance and alertness of caffeine, dextroamphetamine, and modafinil during sleep deprivation. J. Sleep Res. 14, 255-266.
64. Wilson, C., and Terry, A. V. Jr. (2010). Neurodevelopmental animal mod-els of schizophrenia: role in novel drug discovery and development. Clin. Schizophr. Relat. Psychoses 4, 124-137.
65. Young, J. W., Powell, S. B., Risbrough, V., Marston, H. M., and Geyer, M. A. (2009). Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol. Ther. 122, 150-202.